MarsoSPBainSCConsoliA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844. doi:10.1056/NEJMoa1607141
2.
MarsoSPDanielsGHBrown-FrandsenK, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322. doi:10.1056/NEJMoa1603827
3.
HusainMBirkenfeldALDonsmarkM, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841-851. doi:10.1056/NEJMoa1901118
4.
Pi-SunyerXAstrupAFujiokaK, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22. doi:10.1056/NEJMoa1411892
5.
WildingJPHBatterhamRLCalannaS, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989. doi:10.1056/NEJMoa2032183
6.
WaddenTABaileyTSBillingsLK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325:1403-1413. doi:10.1001/jama.2021.1831
7.
RubinoDAbrahamssonNDaviesM, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325:1414-1425. doi:10.1001/jama.2021.3224
8.
UpdikeWHPaneOFranksR, et al. Is it time to expand glucagon-like peptide-1 receptor agonist use for weight loss in patients without diabetes?Drugs. 2021;81:881-893. doi:10.1007/s40265-021-01525-x
